Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study for the Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation in BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a Homologous Recombination Deficiency

NCT05033756 is registered in ClinicalTrials.gov with Institut fuer Frauengesundheit as lead sponsor.

NCT NCT05033756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study for the Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation in BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a Homologous Recombination Deficiency
Lead sponsor
Institut fuer Frauengesundheit
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 30, 2022
Completion date
February 28, 2026
Enrollment
11 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, malignant neoplasm of breast